544 related articles for article (PubMed ID: 16775331)
1. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
Hartman AL; Dover JE; Towner JS; Nichol ST
J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.
Hartman AL; Bird BH; Towner JS; Antoniadou ZA; Zaki SR; Nichol ST
J Virol; 2008 Mar; 82(6):2699-704. PubMed ID: 18199658
[TBL] [Abstract][Full Text] [Related]
3. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.
Hartman AL; Towner JS; Nichol ST
Virology; 2004 Oct; 328(2):177-84. PubMed ID: 15464838
[TBL] [Abstract][Full Text] [Related]
4. A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire.
Boehmann Y; Enterlein S; Randolf A; Mühlberger E
Virology; 2005 Feb; 332(1):406-17. PubMed ID: 15661171
[TBL] [Abstract][Full Text] [Related]
5. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
Basler CF; Mikulasova A; Martinez-Sobrido L; Paragas J; Mühlberger E; Bray M; Klenk HD; Palese P; García-Sastre A
J Virol; 2003 Jul; 77(14):7945-56. PubMed ID: 12829834
[TBL] [Abstract][Full Text] [Related]
6. Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice.
Kiyotani K; Sakaguchi T; Kato A; Nagai Y; Yoshida T
Virology; 2007 Mar; 359(1):82-91. PubMed ID: 17027894
[TBL] [Abstract][Full Text] [Related]
7. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24.
Hoenen T; Groseth A; Kolesnikova L; Theriault S; Ebihara H; Hartlieb B; Bamberg S; Feldmann H; Ströher U; Becker S
J Virol; 2006 Jul; 80(14):7260-4. PubMed ID: 16809331
[TBL] [Abstract][Full Text] [Related]
8. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
[TBL] [Abstract][Full Text] [Related]
9. Evasion of interferon responses by Ebola and Marburg viruses.
Basler CF; Amarasinghe GK
J Interferon Cytokine Res; 2009 Sep; 29(9):511-20. PubMed ID: 19694547
[TBL] [Abstract][Full Text] [Related]
10. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression.
Lefort S; Soucy-Faulkner A; Grandvaux N; Flamand L
J Virol; 2007 Oct; 81(20):10950-60. PubMed ID: 17652396
[TBL] [Abstract][Full Text] [Related]
11. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein.
Hartman AL; Ling L; Nichol ST; Hibberd ML
J Virol; 2008 Jun; 82(11):5348-58. PubMed ID: 18353943
[TBL] [Abstract][Full Text] [Related]
13. Mutations within the human parainfluenza virus type 3 (HPIV 3) C protein affect viral replication and host interferon induction.
Wells G; Addington-Hall M; Malur AG
Virus Res; 2012 Aug; 167(2):385-90. PubMed ID: 22634035
[TBL] [Abstract][Full Text] [Related]
14. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
Fanunza E; Frau A; Corona A; Tramontano E
Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
[TBL] [Abstract][Full Text] [Related]
15. The mengovirus leader protein blocks interferon-alpha/beta gene transcription and inhibits activation of interferon regulatory factor 3.
Hato SV; Ricour C; Schulte BM; Lanke KH; de Bruijni M; Zoll J; Melchers WJ; Michiels T; van Kuppeveld FJ
Cell Microbiol; 2007 Dec; 9(12):2921-30. PubMed ID: 17991048
[TBL] [Abstract][Full Text] [Related]
16. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.
Enterlein S; Warfield KL; Swenson DL; Stein DA; Smith JL; Gamble CS; Kroeker AD; Iversen PL; Bavari S; Mühlberger E
Antimicrob Agents Chemother; 2006 Mar; 50(3):984-93. PubMed ID: 16495261
[TBL] [Abstract][Full Text] [Related]
17. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation.
Donelan NR; Dauber B; Wang X; Basler CF; Wolff T; García-Sastre A
J Virol; 2004 Nov; 78(21):11574-82. PubMed ID: 15479798
[TBL] [Abstract][Full Text] [Related]
18. Rescue of Ebola virus from cDNA using heterologous support proteins.
Theriault S; Groseth A; Neumann G; Kawaoka Y; Feldmann H
Virus Res; 2004 Nov; 106(1):43-50. PubMed ID: 15522446
[TBL] [Abstract][Full Text] [Related]
19. A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β.
Cannas V; Daino GL; Corona A; Esposito F; Tramontano E
J Infect Dis; 2015 Oct; 212 Suppl 2():S277-81. PubMed ID: 25926684
[TBL] [Abstract][Full Text] [Related]
20. Ebola virus defective interfering particles and persistent infection.
Calain P; Monroe MC; Nichol ST
Virology; 1999 Sep; 262(1):114-28. PubMed ID: 10489346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
